Free Newsletter
iPS cells offer scientists a fresh approach to diabetes cure
By taking adult stem cells from patients with Type 1 diabetes and reprogramming them into induced pluripotent stem (iPS) cells, scientists have been able to watch as the disease develops. That front row seat offers a unique perspective that should help researchers advance a cure for the disease.
"What you get is the ability to watch, for the first time, Type 1 diabetes develop," says senior author Douglas Melton, the co-director of the Harvard Stem Cell Institute. "Until you watch a disease develop, you will not understand the mechanism, and you therefore cannot devise any kind of sensible treatment or cure."
The reprogrammed cells can be transformed into insulin-producing pancreatic beta cells, which are destroyed by the disease. "It's completely mind boggling that you can actually study human disease in a dish," Jeanne Loring, a Scripps researcher, tells Technology Review.
- read the story from Technology Review
Related Articles:
'Voila!' Safer patient-specific stem cells
Harvard team uses chemical to reprogram cells
Stem cell summit tackles thorny research issues
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession





SHARE
WITH: